Testing liothyronine with chemotherapy for medulloblastoma that came back
Official title: Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests liothyronine plus chemotherapy for medulloblastoma that came back or kept growing.
Read our full plain-language summary
What the trial team says
This is a Phase 1/Phase 2 study assessing liothyronine (L-T3) immunotherapy and in combination with standard chemotherapy (bevacizumab, irinotecan and temozolomide (BIT)) in children and young adults with medulloblastoma that is relapsed or progressive after standard upfront therapy.
Key facts
- Registry number
- NCT07346157
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent
Where it is running
This trial lists 2 sites.
-
California
- University of California, San Francisco (San Francisco)
-
District of Columbia
- Children's National Hospital (Washington D.C.)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.